The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
Relative imbalances in the expression of estrogen-metabolizing enzymes in the breast tissue of women with breast carcinoma.
Seema Singh; Dhrubajyoti Chakravarti; James A Edney; Ronald R Hollins; Perry J Johnson; William W West; Sheila M Higginbotham; Ercole L Cavalieri; Eleanor G Rogan (Profiled Authors: Ercole Cavalieri; James Augustine Edney; Ronald Ray Hollins; Perry James Johnson; Eleanor G Rogan; William Walter West)
Oncology reports. 2005;14(4):1091-1096.Abstract
Estrogens are a known risk factor for breast cancer. Studies indicate that initiation of breast cancer may occur by metabolism of estrogens to form abnormally high levels of catechol estrogen-3,4-quinones, which can then react with DNA to form depurinating adducts and, subsequently, induce mutations that lead to cancer. Among the key enzymes metabolizing estrogens are two activating enzymes: cytochrome P450 (CYP)19 (aromatase), which converts androgens to estrogens, and CYP1B1, which converts estrogens predominantly to the 4-catechol estrogens that are further oxidized to catechol estrogen-3,4-quinones. Formation of the quinones is prevented by methylation of the 4-catechol estrogens by the enzyme, catechol-O-methyltransferase (COMT). In addition, catechol estrogen quinones can be reduced back to catechol estrogens by NADPH quinone oxidoreductase 1 (NQO1) and/or are coupled with glutathione, preventing reaction with DNA. Thus, COMT and NQO1 are key deactivating enzymes. In this initial study, we examined whether the expression of these four critical estrogen activating/deactivating enzymes is altered in breast cancer. Control breast tissue was obtained from four women who underwent reduction mammoplasty. Breast tissues from five women with breast carcinoma, who underwent mastectomy, were used as cases. The level of expression of CYP19, CYP1B1, COMT and NQO1 mRNAs was quantified from total RNA using a real time RT-PCR method in an ABI PRISM 7700 sequence detection system. The control breast tissues showed lower expression of the activating enzymes, CYP19 and CYP1B1, and higher expression of the deactivating enzymes, COMT and NQO1, compared to the cases. In the cases, the reverse pattern was observed: greater expression of activating enzymes and lower expression of deactivating enzymes. Thus, in women with breast cancer, estrogen metabolism may be related to altered expression of multiple genes. These unbalances appear to be instrumental in causing excessive formation of catechol estrogen quinones that, by reacting with DNA, initiate the series of events leading to breast cancer.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Fang Lu; Muhammad Zahid; Cheng Wang; Muhammad Saeed; Ercole L. Cavalieri; Eleanor G. RoganCancer Prevention Research 2008;1(2):135-145.
W. Yue; R.J. Santen; J.-P. Wang; Y. Li; M.F. Verderame; W.P. Bocchinfuso; K.S. Korach; P. Devanesan; R. Todorovic; E.G. Rogan; et al.Journal of Steroid Biochemistry and Molecular Biology 2003;86(3-5):477-486.
Yan Zhang; Nilesh W. Gaikwad; Kevin Olson; Muhammad Zahid; Ercole L. Cavalieri; Eleanor G. RoganMetabolism: Clinical and Experimental 2007;56(7):887-894.
Appears in this Document